SLC5A1 and chronic kidney disease: The effect of sotagliflozin in the SCORED (Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) trial demonstrated that dual SGLT1 and 2 inhibitor (SGLT1/2i) reduced the risk of primary outcomes of death from cardiovascular causes and hospitalizations and urgent visits for HF across those with diabetes and CKD, regardless of albuminuria.22